Related Experiment Video

Updated: Oct 27, 2025

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.7K

How May Ramucirumab Help Improve Treatment Outcome for Patients with Gastrointestinal Cancers?

Ming-Huang Chen1, Sheng-Nan Lu2, Chien-Hung Chen3

  • 1Taipei Veterans General Hospital, Taipei 11217, Taiwan.

Cancers
|July 24, 2021
PubMed

Insights

Ramucirumab demonstrates efficacy and safety in treating gastrointestinal (GI) cancers, improving outcomes in diverse patient groups. Real-world data confirm its benefits translate from clinical trials to actual patient care.

Area of Science:

  • Oncology
  • Gastroenterology
  • Clinical Pharmacology

Background:

  • Gastrointestinal (GI) cancers exhibit high recurrence rates and poor prognoses, necessitating novel therapeutic strategies.
  • Current treatment options for advanced GI cancers have limitations, highlighting the need for effective systemic therapies.

Purpose of the Study:

  • To review the efficacy and safety of ramucirumab in GI cancers based on Phase 3 randomized controlled trials (RCTs).
  • To evaluate ramucirumab's performance in pre-specified subgroups and real-world clinical practice.
  • To assess the impact of ramucirumab on overall survival (OS), progression-free survival (PFS), and quality of life (QOL).

Main Methods:

  • Narrative review of published Phase 3 RCTs involving ramucirumab in GI cancers.
  • Inclusion of data from real-world clinical practice worldwide.
  • Analysis of efficacy endpoints (OS, PFS) and safety profiles.
  • Consideration of patient subgroups and QOL data where available.

Main Results:

  • Ramucirumab showed significant efficacy and a favorable safety profile across overall patient populations in Phase 3 trials.
  • Consistent benefits were observed in pre-specified subgroups, including those with difficult-to-treat disease.
  • Real-world data corroborated Phase 3 trial findings, demonstrating similar survival outcomes even in patients with complications.

Conclusions:

  • Ramucirumab is an efficacious, safe, and tolerable treatment option for patients with GI cancers.
  • The therapeutic benefits of ramucirumab observed in clinical trials are transferable to real-world clinical settings.
  • Ramucirumab offers a valuable approach to improve treatment outcomes for patients battling GI malignancies.
Keywords:
angiogenesiscolorectal cancergastric cancergastrointestinalhepatocellular carcinomaramucirumab

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.4K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

708

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
291
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
280
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
264
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
845
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
251